Comparison of the Therapeutic Effect of the Combination Regimen of Oral Melatonin and Topical Betamethasone with Topical Betamethasone Alone in the Treatment of Atopic Dermatitis: A Randomized Clinical Trial

Document Type : Original Article(s)

Authors

1 Assistant Professor, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

2 MD, Dermatologist, Skin Diseases and Leishmaniasis Research Center, Isfahan, Iran

3 Professor, Department of Dermatology, School of Medicine, Skin Diseases and Leishmaniasis Research Center Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Department of Epidemiology and Biostatistics, School of Health Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 General Practitioner, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

6 General Practitioner, Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Atopic dermatitis is a common disease in infants and children which is chatacterized with pruritus and skin lesions and is known to be chronic and recurrent. Since the side effects caused by common treatments (topical corticosteroids) may cause a limitation to their long-term use, the need for alternative treatments is mandatory. Considering the anti-inflammatory effects, immune system, and sleep-regulating properties of melatonin, this study compared the effects of topical betamethasone alone with topical betamethasone combined with oral melatonin in the atopic treatment dermatitis.
Methods: This clinical trial was carried out on 50 patients with atopic dermatitis. Participants were randomly assigned to two treatment groups. The control group received betamethasone, and the intervention group, in addition to betamethasone, received 3 mg melatonin tablets for 12 weeks. The disease status of participants was also assessed using the Scoring Atopic Dermatitis (SCORAD) scale.
Findings: Both treatment groups showed significant changes in SCORAD score, affected area, disease intensity, and reported symptoms like insomnia and itching. So, the SCORAD index in the intervention and control groups decreased on average by 29.44 ± 14.09 and 33.56 ± 16.08, respectively, at the end of the treatment. But, no significant difference was observed between the two groups in these changes. Additionally, no specific treatment-related side effects also were reported during this study.
Conclusion: Although both treatment regimens resulted in significant improvement in the condition of atopic dermatitis, this study found no significant difference in the effectiveness of the two treatment regimens, suggesting the need for further investigation into alternative topical corticosteroid therapies to provide similar efficacy with reduced side effects.

Highlights

Fariba Iraji: PubMed ,Google Scholar

Keywords

Main Subjects

References

  1. Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE–and Institute of Medicine–based recommendations. Ann Allergy Asthma Immunol 2024; 132(3): 274-312.
  2. Chu AW, Wong MM, Rayner DG, Guyatt GH, Martinez JPD, Ceccacci R, et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 2023; 152(6): 1470-92.
  3. McKenzie C, Silverberg JI. The prevalence and persistence of atopic dermatitis in urban United States children. Ann Allergy Asthma Immunol 2019; 123(2): 173-8. e1.
  4. Darabi B, Rizehbandi M, Shokri M, Shokri F, Bastani E. Prevalence of pediatric atopic dermatitis in Iran: A Systematic review and meta-analysis. International Journal of Pediatrics. 2023;11(4): 17673-84.
  5. Libon F, Caron J, Nikkels AF. Biomarkers in atopic dermatitis. Dermatol Ther (Heidelb) 2024; 14(7): 1729–38.
  6. Mehrpooya M, Ghaed-Amini F, Firozian F, Mohammadi Y, Alirezaei P. Beneficial effects of adding topical atorvastatin 5% cream to topical betamethasone 1% ointment on chronic hand eczema. Arch Iran Med 2020; 23(9): 605-13.
  7. Ständer S. Atopic dermatitis. N Engl J Med 2021; 384(12): 1136-43.
  8. Kader HA, Azeem M, Jwayed SA, Al-Shehhi A, Tabassum A, Ayoub MA, et al. Current insights into immunology and novel therapeutics of atopic dermatitis. Cells 2021; 10(6): 1392.
  9. Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician 2021; 103(6): 337-43.
  10. Harvey J, Lax SJ, Lowe A, Santer M, Lawton S, Langan SM, et al. The long‐term safety of topical corticosteroids in atopic dermatitis: A systematic review. Skin Health Dis 2023; 3(5): e268.
  11. Blauvelt A, Papp KA, Griffiths CE, Puig L, Weisman J, Dutronc Y, et al. Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and-3). Am J Clin Dermatol 2017; 18(2): 273-80.
  12. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75(3): 494-503. e6.
  13. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397(10290): 2151-68.
  14. Iraji F, Farhadi S, Faghihi G, Mokhtari F, Basiri A, Jafari-Koshki T, et al. Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: A randomized controlled trial. Adv Biomed Res 2015; 4: 228.
  15. Maldonado MD, Gutiérrez-Pérez MC, Flores JA, Ales E. Melatonin reduces exo-endocytosis in mast cells, making it a useful therapeutic tool in inflammatory diseases. Ann Allergy Asthma Immunol 2023; 131(5): 670-2.
  16. Hu X, Li J, Wang X, Liu H, Wang T, Lin Z, et al. Neuroprotective effect of melatonin on Sleep disorders Associated with Parkinson’s Disease. Antioxidants (Basel) 2023; 12(2): 396.
  17. Jaworek AK, Jaworek M, Szafraniec K, Wojas-Pelc A, Szepietowski J. Melatonin and sleep disorders in patients with severe atopic dermatitis. Postepy Dermatol Alergol 2021; 38(5): 746-51.
  18. Jaworek AK, Szepietowski JC, Hałubiec P, Wojas-Pelc A, Jaworek J. Melatonin as an antioxidant and immunomodulator in atopic dermatitis—A new look on an old story: A Review. Antioxidants (Basel) 2021; 10(8): 1179.
  19. Pereira MBTC, Souza LTdLD, de Carvalho Ferreira D, Estefan J. Treatment of sleep disorders in children with atopic dermatitis: what's new? Journal of Experimental Neurology 2024; 5(2): 65-72.
  20. Menczel Schrire Z, Phillips CL, Chapman JL, Duffy SL, Wong G, D’Rozario AL, et al. Safety of higher doses of melatonin in adults: a systematic review and meta‐analysis. J Pineal Res 2022; 72(2): e12782.
  21. Böhme M, Svensson Å, Kull I, Wahlgren CF. Hanifin's and Rajka's minor criteria for atopic dermatitis: which do 2-year-olds exhibit? J Am Acad Dermatol 2000; 43(5): 785-92.
  22. Kim TH, Jung JA, Kim GD, Jang AH, Ahn HJ, Park YS, et al. Melatonin inhibits the development of 2, 4‐dinitrofluorobenzene‐induced atopic dermatitis‐like skin lesions in NC/Nga mice. J Pineal Res 2009; 47(4): 324-9.
  23. Chang Y-S, Lin M-H, Lee J-H, Lee P-L, Dai Y-S, Chu K-H, et al. Melatonin supplementation for children with atopic dermatitis and sleep disturbance: a randomized clinical trial. JAMA Pediatr 2016; 170(1): 35-42.
  24. Taghavi Ardakani A, Farrehi M, Sharif MR, Ostadmohammadi V, Mirhosseini N, Kheirkhah D, et al. The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: a randomized, double‐blinded, placebo‐controlled trial. Pediatr Allergy Immunol 2018; 29(8): 834-40.
  25. Guo M, Su J, Zheng S, Chen B. Objective sleep in atopic dermatitis: a meta-analysis. Dermatitis 34(2): 145-50.
  26. Samynathan A, Fishbein AB, Abbott SM, Booster GD, Zee PC, Sheldon SH, et al. Assessment and Management of Sleep Disturbances in Atopic Dermatitis: A Review. Dermatitis 2024; 35(S1): S7-S12.
  27. Chaudhari R, Gosavi S, Bornare P, Sonawane S, Ahire T. An overview of antihistamines and their properties used for treatment of different diseases. Antiinflamm Antiallergy Agents Med Chem 2023; 22(4): 220-9.
  28. García JJ, López‐Pingarrón L, Almeida‐Souza P, Tres A, Escudero P, García‐Gil FA, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res 2014; 56(3): 225-37.
  29. Chang Y-S, Chou Y-T, Lee J-H, Lee P-L, Dai Y-S, Sun C, et al. Atopic dermatitis, melatonin, and sleep disturbance. Pediatrics 2014; 134(2): e397-e405.
  30. Çikler E, Ercan F, Çetinel Ş, Contuk G, Şener G. The protective effects of melatonin against water avoidance stress-induced mast cell degranulation in dermis. Acta Histochem 2005; 106(6): 467-75.
Journal of Isfahan Medical School
Volume 42, Issue 782
2nd Week, November
November and December 2024
Pages 774-782

Files

History

  • Receive Date: 13 March 2024
  • Accept Date: 03 November 2024

Share

How to cite

Statistics